Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 31;21(7):41.
doi: 10.1007/s11882-021-01018-7.

Non-IgE-Mediated Drug Hypersensitivity Reactions

Shyam R Joshi  1 , David A Khan  2
Affiliations
Review

Non-IgE-Mediated Drug Hypersensitivity Reactions

Shyam R Joshi et al. Curr Allergy Asthma Rep. .

Abstract

Purpose of review: Non-IgE-mediated drug reactions have traditionally been poorly defined and studied, though they are the most common form of hypersensitivity. Their presentations are highly variable and can range in severity from mild, cutaneous-only reactions to severe systemic disease.

Recent findings: The most notable advance in non-IgE-mediated hypersensitivity reactions is in diagnostics. HLA alleles have traditionally been used for identifying certain patients at risk for abacavir hypersensitivity syndrome, but more recent studies have shown several other HLA alleles associated with severe cutaneous adverse reactions with various medications. This article also highlights the use of delayed intradermal testing for radiocontrast media and patch testing for delayed antibiotic reactions. Drug reactions remain a major cause of morbidity and reason for treatment changes. Non-IgE-mediated reactions have had an increase in research interest over the past decade with an increased emphasis on better understanding the clinical presentation and underlying pathophysiology.

Keywords: Anaphylactoid; Delayed hypersensitivity reaction; Drug reaction with eosinophilia and systemic symptoms (DRESS); Non-IgE-mediated drug allergy; Stevens-Johnson syndrome (SJS); Toxic epidermal necrolysis (TEN).

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as:
• Of importance
•• Of major importance
    1. Wong A, Seger DL, Lai KH, Goss FR, Blumenthal KG, Zhou L. Drug hypersensitivity reactions documented in electronic health records within a large health system. J Allergy Clin Immunol Pract. 2019;7(4):1253-60.e3. https://doi.org/10.1016/j.jaip.2018.11.023 Epub 2018 Dec 1.
    1. Gomes ER, Demoly P. Aug Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005;5(4):309-16. https://doi.org/10.1097/01.all.0000173785.81024.33 PMID: 15985812.
    1. Dispenza MC. Classification of hypersensitivity reactions. Allergy Asthma Proc. 2019;40(6):470-73. https://doi.org/10.2500/aap.2019.40.4274 PMID: 31690397.
    1. Sullivan A, Wang E, Farrell J, Whitaker P, Faulkner L, Peckham D, et al. Beta-lactam hypersensitivity involves expansion of circulating and skin-resident TH22 cells. The Journal of Allergy and Clinical Immunology 2018; 141(1): 235–49 e8.
    1. Monroy-Arreola A, Duran-Figueroa NV, Mendez-Flores S, Dominguez-Cherit J, Watkinson J, Badillo-Corona JA, et al. Up-regulation of T-cell activation microRNAs in drug-specific CD4(+) T-cells from hypersensitive patients. Chem Res Toxicol. 2018;31(6):454–61. - PubMed - DOI

LinkOut - more resources